ALMIRALL (E2Z BE) stock market data APIs
€11.4829
0.04(0.3%)
as of March 18, 2026
Try our APIs with
free plan!
ALMIRALL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for E2Z.BE.
Prev. Close
11.4829
Open
11.5217
High
11.5951
Low
11.4764
52 wk Range
8.6637-13.26
Market Cap
1 925 M
Dividends (Yield)
0.0198
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ALMIRALL data using free add-ons & libraries
Get ALMIRALL Fundamental Data
ALMIRALL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ALMIRALL News
New
etherna's intratumoral mRNA/LNP platform advances to clinical testing in nonmelanoma skin cancer led by Almirall
NIEL, Belgium, Feb. 24, 2026 /PRNewswire/ -- etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one of its ...
Almirall SA (LBTSF) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Investments
This article first appeared on GuruFocus. Net Sales: EUR 1,108 million, a 12.4% increase year-on-year. EBITDA: EUR 233 million, up 21% year-on-year. Gross Margin: 64.4% for the year. R&D Investment: ...
Almirall’s 2025 Results
Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial executi...
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
